v3.24.3
Stockholders’ Equity (Tables)
 9 Months Ended
Sep. 27, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plan and our Amended ESPP as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Research and development$8,764 $12,438 $21,834 $25,279 
Selling, general and administrative14,259 28,040 45,656 56,760 
Total stock-based compensation expense$23,023 $40,478 $67,490 $82,039 
Stock-based compensation expense for each type of award under our equity incentive plan and Amended ESPP were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Stock options$1,397 $1,882 $4,659 $5,966 
Restricted stock units20,626 18,440 58,224 50,804 
Performance stock units370 19,463 2,194 22,129 
Employee stock purchase plan
630 693 2,413 3,140 
Total stock-based compensation expense$23,023 $40,478 $67,490 $82,039 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following weighted-average assumptions to determine the weighted-average grant date fair value of $20.19 per share for the 2024 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$21.71 
Expected volatility
36.68 %
Risk-free interest rate
4.42 %
Dividend yield
— %